TP53 and neoplasm: Using this standard for chemoresponsiveness, we first performed a PLA assessment in EOC tumor sections (n = 41 pairs) of different histological subtypes (36 HGS, 4 clear cell, and 1 endometrioid) obtained pre- and post-chemotherapy from the same EOC patients (Figure 1A,B), in order to determine whether nuclear localization of HKII-P-p53 (Ser15) interaction is associated with prognosis and chemoresponsiveness as determined by the length of progression-free interval [36,37] (Table S3).